Novo’s Obesity Pill Hits Shelves as Comeback Medicine for Battered Stock
Novo Nordisk is fighting to reclaim control of its narrative. The drugmaker is betting on America’s first GLP-1 obesity pill to restore investor confidence after its worst year in decades. Entering 2026 under pressure from pricing battles, leadership churn, and rising competition from Eli Lilly, the company is rolling out an oral Wegovy priced from $149/mo to widen access and push back against cheap copycats.
- Trial data shows the highest Wegovy pill dose drove 16.6% weight loss over 64 weeks, beating Lilly’s oral orforglipron, which showed 12.4% weight loss over 72 weeks.
- The starter dose is already available in 70K+ US pharmacies, including CVS and Costco, plus Ro and WW International, with higher doses arriving this week.
The clock’s ticking: Sydbank analyst Søren Løntoft Hansen believes Novo is in a “must-win” moment in the US, noting the situation seems like a “show-me case” for skeptical investors. Patent expirations abroad and pressure for Most Favored Nation pricing threaten revenue just as competition from Lilly heats up. With Goldman Sachs seeing oral GLP-1s grabbing 24% of the 2030 market, Novo can’t afford to miss again.
